Table 4. Clinical and Pathological Characteristics of Incident Prostate Cancers.
| Placebo (n=8,696) |
Vitamin E alone (n=8,737) |
Selenium alone (n=8,752) |
Vitamin E + selenium (n=8,702) |
|||||
|---|---|---|---|---|---|---|---|---|
| TOTAL PROSTATE CANCERS DIAGNOSED | 529 | 620 | 575 | 555 | ||||
| Number as of unblinding (primary paper) | 416 | 79% | 473 | 76% | 432 | 75% | 437 | 79% |
| Number diagnosed prior to unblinding but data received afterwards | 26 | 5% | 33 | 5% | 22 | 4% | 17 | 3% |
| Number diagnosed after unblinding | 87 | 16% | 114 | 18% | 121 | 21% | 101 | 18% |
| CONFIRMATION STATUS | ||||||||
| Confirmed by central pathology* | 444 | 84% | 506 | 82% | 474 | 82% | 475 | 86% |
| T-STAGE | ||||||||
| TX | 5 | 1% | 9 | 1% | 7 | 1% | 8 | 1% |
| T1a-c | 375 | 72% | 460 | 75% | 425 | 76% | 391 | 72% |
| T2a-b | 143 | 27% | 138 | 23% | 127 | 23% | 144 | 26% |
| T3a-b | 1 | 0% | 3 | 0% | 3 | 1% | 2 | 0% |
| Not staged | 5 | 10 | 13 | 10 | ||||
| N-STAGE | ||||||||
| NX | 378 | 72% | 441 | 73% | 397 | 70% | 393 | 72% |
| N0 | 145 | 28% | 167 | 27% | 166 | 29% | 154 | 28% |
| N1 | 0 | 0% | 0 | 0% | 2 | 0% | 1 | 0% |
| Not staged | 6 | 12 | 10 | 7 | ||||
| M-STAGE | ||||||||
| MX | 364 | 70% | 435 | 72% | 399 | 71% | 391 | 72% |
| M0 | 159 | 30% | 170 | 28% | 159 | 28% | 153 | 28% |
| M1a-c | 0 | 0% | 3 | 0% | 7 | 1% | 3 | 1% |
| Not staged | 6 | 12 | 10 | 8 | ||||
| GLEASON SCORE | ||||||||
| 4 - 6 | 286 | 69% | 310 | 67% | 281 | 64% | 281 | 63% |
| 7 | 102 | 24% | 118 | 25% | 135 | 31% | 124 | 28% |
| 8 - 10 | 31 | 7% | 37 | 8% | 26 | 6% | 40 | 9% |
| Not graded | 110 | 155 | 134 | 110 | ||||
*
There were no disagreements. The cases not confirmed by central pathology review were either because no materials or inadequate materials were sent for review.